Induction of sodium iodide symporter gene and molecular characterisation of HNF3β/FoxA2, TTF-1 and C/EBPβ in thyroid carcinoma cells by Akagi, T et al.
Induction of sodium iodide symporter gene and molecular
characterisation of HNF3b/FoxA2, TTF-1 and C/EBPb in thyroid
carcinoma cells
T Akagi*,1,2,6, QT Luong
1,2,6, D Gui
3, J Said
2, J Selektar
2, A Yung
1, CM Bunce
4, GD Braunstein
5 and
HP Koeffler
1,2
1Division of Hematology and Oncology, Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA;
2Samuel
Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA;
3Department of Pathology, UCLA
School of Medicine, Los Angeles, CA, USA;
4School of Biosciences, University of Birmingham, Birmingham, B15 2TT, UK;
5Division of Endocrinology,
Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
Thyroid carcinoma cells often do not express thyroid-specific genes including sodium iodide symporter (NIS), thyroperoxidase
(TPO), thyroglobulin (TG), and thyrotropin-stimulating hormone receptor (TSHR). Treatment of thyroid carcinoma cells (four
papillary and two anaplastic cell lines) with histone deacetylase inhibitors (SAHA or VPA) modestly induced the expression of the NIS
gene. The promoter regions of the thyroid-specific genes contained binding sites for hepatocyte nuclear factor 3 b (HNF3b)/forkhead
box A2 (FoxA2), thyroid transcription factor 1 (TTF-1), and CCAAT/enhancer binding protein b (C/EBPb). Quantitative reverse
transcription-polymerase chain reaction (RT–PCR) showed decreased expression of HNF3b/FoxA2 and TTF-1 mRNA in papillary
thyroid carcinoma cell lines, when compared with normal thyroid cells. Forced expression of these genes in papillary thyroid
carcinoma cells inhibited their growth. Furthermore, the CpG island in the promoter region of HNF3b/FoxA2 was aberrantly
methylated; and treatment with 5-aza-2-deoxycytidine (5-Az) induced its expression. Immunohistochemical staining showed that
C/EBPb was localised in the nucleus in normal thyroid cells but was detected in the cytoplasm in papillary thyroid carcinoma cells.
Subcellular fractionation of papillary thyroid carcinoma cell lines also demonstrated high levels of expression of C/EBPb in the
cytoplasm, suggesting that a large proportion of C/EBPb protein is inappropriately localised in the cytoplasm. In summary, these
findings reveal novel abnormalities in thyroid carcinoma cells
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Development of thyroid carcinoma is accompanied by a block of
differentiation of these cells. Papillary and follicular thyroid
carcinomas initially are relatively well-differentiated tumours that
over time may de-differentiate, whereas anaplastic thyroid
carcinoma is an undifferentiated tumour (Farid et al, 1994).
Poorly differentiated or undifferentiated carcinomas no longer
express mature thyroid-specific genes including sodium iodide
symporter (NIS), thyroperoxidase (TPO), thyroglobulin (TG), and
thyrotropin-stimulating hormone receptor (TSHR). In normal
thyroid cells, TSHR is stimulated by thyrotropin-stimulating
hormone, resulting in the activation of NIS, which incorporates
iodine. Thyroglobulin and iodine are catalysed into thyroid
hormones by TPO (Carrasco, 1993). Investigators have predomi-
nantely attempted to induce differentiation of thyroid cancer cells
by exposure to compounds associated with known differentiation
of other cancers.
Retinoic acid, including all-trans retinoic acid (ATRA) and 9-cis
retinoic acid (9-cis RA), induces differentiation of acute promye-
locytic leukaemia cells and neuroblastoma cells and is used in the
therapy for these cancers. Retinoids have been reported to induce
the expression of TPO, TG, and NIS mRNAs in thyroid carcinoma
cell lines (Schmutzler et al, 1997; Haugen, 2004). The NIS promoter
contains CpG islands, and a DNA demethylating agent (such as,
5-aza-2-deoxycytidine (5-Az)) combined with a histone deacetylase
inhibitor has been shown to induce NIS expression and radioactive
iodine uptake in follicular and anaplastic thyroid carcinoma cell
lines (Venkataraman et al, 1999; Haugen, 2004).
The transcription factors of paired box gene 8 (Pax-8) and
thyroid transcription factor 1 (TTF-1) have been analysed in
thyroid cells. Paired box gene 8 is necessary for the formation of
thyroxine-producing follicular cells in the thyroid gland (Mansouri
et al, 1998, 1999); and fusion of the Pax-8 and peroxisome
proliferator-activated receptor g (PPARg) genes occurs in approxi-
mately 30% of follicular thyroid carcinomas (Kroll et al, 2000;
Dwight et al, 2003). Thyroid transcription factor 1 is required for
the development of the thyroid gland, and TTF-1-deficient mice
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slack a thyroid gland and die at birth (Kimura et al, 1996). The
expression of Pax-8 and TTF-1 is low in thyroid carcinoma
(Ros et al, 1999); and stable transfection with a Pax-8 expression
vector in anaplastic thyroid carcinoma cell line, ARO, caused
re-expression of endogenous NIS, TG, and TPO (Presta et al, 2005).
Reporter gene analysis found that the promoter region of TG, TPO,
and TSHR could be activated by the forced expression of either
Pax-8 or TTF-1 in the papillary thyroid carcinoma cell line NPA
(Ros et al, 1999). Co-transfection of Pax-8 and TTF-1 restored TG
promoter activity in WRO (follicular thyroid carcinoma) and ARO
cells (Chun et al, 1998).
In this study, we attempted to induce differentiation of papillary
and anaplastic thyroid carcinoma cells as measured by the
induction of NIS, TPO, TG, and TSHR by exposing the cells to
5-Az, histone deacetylase inhibitors (suberoylanilide hydroxamic
acid (SAHA) and valproic acid), ATRA, 9-cis RA, troglitazone
(PPARg ligand), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), thyroid
hormone T3, and thyrotropin-stimulating hormone. Furthermore,
dysregulation of three transcription factors (TTF-1, hepatocyte
nuclear factor 3 b (HNF3b)/forkhead box A2 (FoxA2), and
CCAAT/enhancer binding protein b (C/EBPb)) was examined in
thyroid carcinoma cells.
MATERIALS AND METHODS
Cell culture and drug treatments
BHP (sublines 2–7, 7–13, 10-3 and 18–21) and NPA papillary, and
ARO and FRO anaplastic thyroid carcinoma cell lines were
cultured as described before (Fagin et al, 1996; Ohta et al, 1997;
Luong et al, 2006). The normal rat thyroid cell line FRTL-5 cells
(from Dr Shlomo Melmed at Cedars-Sinai Medical Center) were
cultured in Ham’s F12K medium (Invitrogen, Carlsbad, CA, USA)
with 5% bovine calf serum (Invitrogen) together with 10mUml
 1
thyrotropin-stimulating hormone, 0.01mgml
 1 insulin, 10nM
hydrocortisone, 5ngml
 1 transferrin, 10ngml
 1 somatostatin,
and 10ngml
 1 glycyl-L-histidyl-L-lysine acetate.
Cultured cells were treated with the following agents either alone
or in combinations with 5-Az (1mM), SAHA (5mM), valproic acid
(1mM), ATRA (100nM), 9-cis RA (100nM), troglitazone (PPARg
ligand, 10mM), 1,25(OH)2D3 (1mM), thyroid hormone T3 (10nM),
and thyrotropin-stimulating hormone (1mUml
 1) for 48–96h.
5-Aza-2-deoxycytidine, valproic acid, thyroid hormone T3, and
thyrotropin-stimulating hormone were dissolved in water; SAHA
and troglitazone were diluted in dimethyl sulphoxide (DMSO);
ATRA, 9-cis RA, and 1,25(OH)2D3 were placed in ethanol. Equal
volume of DMSO and ethanol were added in control samples.
Real-time reverse transcription polymerase chain reaction
Total RNA was isolated from thyroid carcinoma cell lines and
normal thyroid tissues using Trizol reagent (Invitrogen), and
cDNA was prepared from 1mg of total RNA with Superscript III
reverse transcriptase (Invitrogen). Expression of mRNAs was
measured by real-time PCR using an iCycler iQ system (Bio-Rad,
Hercules, CA, USA) as described previously (Xie et al, 2001). To
determine the expression levels of NIS, C/EBPa, and C/EPBb with
probes, amplification reactions were performed with the Universal
Taqman PCR mastermix (Applied Biosystems, Foster City, CA,
Table 1 Primer and probe sequences used for real-time RT–PCR
Gene name Sequence Melt. Temp. Size
NIS S CCCTCATCCTGAACCAAGTG — 230bp
AS GATCCGGGAGTGGTTCTG
probe CTGGACATCTGGGCGTCGCTC
TPO S ACCTCGACGGTGATTTGCA 82.01C7 1 b p
AS CCGCCTGTCTCCGAGATG
TG S GTGCCAACGGCAGTGAAGT 81.01C8 7 b p
AS TCTGCTGTTTCTGTAGCTGACAAA
TSHR S CCCAGCTTACCGCCCAGT 81.01C7 9 b p
AS TAGAAAATGCATGACTTGGAATAGTTC
HNF3b/FoxA2 S AAGACCTACAGGCGCAGCTA 87.01C 214bp
AS CCTTCAGGAAACAGTCGTTGA
TTF-1 S GCCGTACCAGGACACCATGAG 86.01C 265bp
AS CAGGTACTTCTGTTGCTTGAAG
Pax-8 S AAGTCCAGCATTGCGGCACA 84.01C 331bp
AS GAGGGAAGTGCTTATGGTCC
C/EBPa S TGGACAAGAACAGCAACGAG — 130bp
AS TTGTCACTGGTCAGCTCCAG
probe CACCTTCTGCTGCGTCTCCACGTT
C/EBPb S GACAAGCACAGCGACGAGTA — 102bp
AS GTGCTGCGTCTCCAGGTT
probe ATC TTG GCC TTG TCG CGG CTC TT
18S S AAACGGCTACCACATCCAAG 83.01C 155bp
AS CCTCCAATGGATCCTCGTTA
b-actin S CCCAGATCATGTTTGAGACC 87.01C 154bp
AS AGGGCATACCCCTCGTAGAT
AS, anti-sense primer; Melt. Temp., melting temperature; RT–PCR, reverse transcription-polymerase chain reaction; S, sense primer.
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sUSA). Expression levels of TPO, TG, TSHR, HNF3b/FoxA2, TTF-1,
and Pax-8 were measured with platinum Taq DNA Polymerase
(Invitrogen) and SYBRGreen I (Molecular Probes, Carlsbad, CA,
USA). Expression levels of target genes were normalised with 18S
or b-actin. Specificity of all PCR products was checked on agarose
gel, and only one product of the correct size was observed for each
primer pair. Sequences of primers and probes, the melting
temperature, and product size are shown in Table 1.
Radioactive iodine (
125I) uptake assay
Na
125I (100mCiml
 1) stock was diluted to 0.02mCiml
 1 using
Hanks’ Balanced Salt Solution (HBSS). Cells were plated at 1 10
5
cells per well in 12-well plates and treated with appropriate drugs,
either with or without 10 mUml
 1 thyrotropin-stimulating
hormone and/or cold (unlabelled) NaI. For radioactive iodine
uptake, cells were washed twice with HBSS and 500mlo fN a
125I
working solution was added. After incubation for 3h at 371C, cells
were washed with 1ml cold HBSS and lysed with 1ml of 95%
ethanol for 1h at 371C. Lysates were transferred to vials for
counting, and total counts were normalised to number of viable
cells in parallel cultures.
Plasmid transfection and colony assay
Expression vectors of pTTF-1 and pHNF3b/FoxA2 were generous
gifts from Dr Edward Morrisey (University of Pennsylvania).
Plasmids of 1mg pTag1 (empty vector), pTTF-1, and pHNF3b/
FoxA2 were transfected into BHPs cells using Lipofectamine 2000
(Invitrogen). The zinc-inducible pMT-C/EBPb expression plasmid
(Gery et al, 2005) was transfected into BHP cells (sublines 2–7 and
7–13), which were selected with 500mgml
 1 G418 for 48h.
For colony assay, cells transfected with plasmid were plated at
1 10
5 cells per well in 12-well plates in 1ml culture media
containing 500mgml
 1 G418. After 2 weeks, cells were stained with
Crystal violet dye (0.25% crystal violet dissolved in 50% methanol).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide and clonogenic soft agar assay
Cells were treated with 10ml of 5mgml
 1 MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich,
St Louis, MO, USA), and incubated at 371C for 4h. Medium
was removed, and 50ml DMSO was added to the cells to solubilise
the MTT. Plates were read at wavelength of 540nm on a plate
reader.
For clonogenic soft agar assays, cells were plated into 24-well flat-
bottomed wells using a two-layer soft agar system with 1 10
3cells
per well in a volume of 400ml per well as previously described (Luong
et al, 2006). After 14 days of incubation, colonies were counted.
Methylation analysis of HNF3b/FoxA2 gene
Genomic DNA was modified by sodium bisulphate using EZ
DNA Methylation Kit (Zymo Research, Orange, CA, USA). The
CpG island ( 761 to  561, ATG codon considered as þ1) of the
HNF3b/FoxA2 gene was amplified from the bisulphate-modified
genomic DNA with specific primers (sense primer: 50-TTTTAGGG
GATTTGTTGTGG-30, anti-sense primer: 50-AAATAATCAACTCAC
ACC-30). For PCR amplification, a total volume of 10ml was used
containing modified genomic DNA, 0.5mM of each primers,
5.0ml of FailSafe PCR 2  PreMixe E (Epicentre Biotechno-
logies, Madison, WI, USA) and 1.0U platinum Taq (Invitrogen).
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Figure 1 Induction of NIS expression in anaplastic and papillary thyroid carcinoma cell lines with SAHA and ligands of nuclear hormone receptors.
Thyroid carcinoma cells (ARO and BHP) were cultured with or without 1,25(OH)2D3 (VD3, 1mM), all-trans retinoic acid (ATRA, 100nM), 9-cis retinoic acid
(9-cis RA, 100nM), troglitazone (Trog, 10mM), or thyroid hormone T3 (TH, 10nM), either with or without SAHA (5mM). Expression of NIS mRNA in these
cells was measured by quantitative RT–PCR after 48h exposure. NIS expression was compared with levels present in normal thyroid cells. Relative levels of
transcripts for NIS were normalised to 18S RNA transcripts within each sample. Level of NIS expression is the mean of n¼3 samples.
Differentiation induction of thyroid cancer
T Akagi et al
783
British Journal of Cancer (2008) 99(5), 781–788 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sPolymerase chain reaction products were subcloned into pCR 2.1
vector (Invitrogen) and sequenced.
Subcellular fractionation, Western blot analysis, and
immunohistochemistry
Total cell lysates were prepared by lysing cells in RIPA buffer (1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM
Tris-HCl (pH 7.5)) containing a protease inhibitor cocktail (Roche
Diagnostics GmbH, Mannheim, Germany) as well as 1mM NaF
and 1mM NaVO4. To separate nuclear and cytoplasmic fractions,
cells were fractionated with NE-PER Nuclear and Cytoplasmic
Extraction Reagent (Pierce Biotechnology, Rockford, IL, USA).
These samples were subjected to sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) followed by an
electrotransfer to polyvinylidene difluoride membrane. The signals
were developed with either Supersignal West Pico Chemilumines-
cent or Supersignal West Dura Extended Duration Substrate
(Pierce Biotechnology). Anti-PPARg, C/EBPb, b-actin, and hetero-
geneous nuclear ribonuclear protein (hnRNP) A1 antibodies were
obtained from Santa Cruz Technology (Santa Cruz, CA, USA).
Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
from Research Diagnostics Inc. (Concord, MA, USA).
Normal and papillary thyroid carcinoma tissue blocks were
cut at 3mM thickness, deparaffinised and pre-treated in Tris-HCl
(pH 9.0). These samples were incubated overnight with
anti-C/EBPb antibody (1:500 dilution), washed, followed by the
HRP-conjugated secondary antibody (Dako, Carpinteria, CA,
USA), and DAB chromogen. The tissues were counterstained with
haematoxylin and then coverslipped. Three samples of normal and
three carcinomas were examined.
RESULTS
Induction of expression of thyroid-specific genes: effect
of 5-Az, SAHA, valproic acid, and nuclear hormone
receptor ligands in thyroid carcinoma cell lines
Silencing of genes can be associated with epigenetic change
including abnormal methylation of CpG islands and/or deacetyl-
ation of histones. Therefore, papillary (BHP sublines 2–7, 7–13,
10-3, and 18–21) and two anaplastic thyroid carcinoma (ARO and
FRO) cell lines were cultured either with or without 5-Az (1mM)
and/or histone deacetylase inhibitors (SAHA (5mM) or valproic
acid (1mM)). Quantitative reverse transcription-polymerase chain
reaction (RT–PCR) showed that expressions of thyroid-specific
genes (TPO, TG, and TSHR) were either extremely low or at
undetectable levels compared with normal thyroid tissue (data not
shown).
We also examined the effects of several ligands of nuclear
hormone receptors either with or without SAHA. As shown in
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Figure 2 Expression of transcription factors in normal thyroid cells and thyroid carcinoma cell lines. Expression of transcription factors including HNF3b/
FoxA2, TTF-1, Pax-8, C/EBPa, and C/EBPb was measured by quantitative RT–PCR in five normal thyroid samples and five thyroid carcinoma cell lines (BHPs
2–7, 7–13, 18–21, ARO, and FRO). Expression in individual samples or cell lines is represented by open circles, mean expression of normal or cancer cells
is represented by the horizontal bar±s.e.
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sFigure 1, 1,25(OH)2D3, ATRA, 9-cis RA, troglitazone, or thyroid
hormone T3 alone was able to induce the expression of NIS mRNA
in ARO and BHP (sublines 2–7 or 10–3) cells. The combination of
SAHA with ATRA, 9-cis RA, troglitazone, or thyroid hormone T3
did not enhance the expression of NIS compared with SAHA alone
in BHP papillary thyroid carcinoma cells (sublines 2–7 and 10–3).
Thyroid-related transcription factors are poorly expressed
in papillary and anaplastic thyroid carcinoma cell lines
The above data showed that the four thyroid-specific genes (NIS,
TPO, TG, and TSHR) were negligibly expressed in the thyroid
carcinoma cell lines; therefore, common transcription factor(s)
that regulate these genes might not be expressed in these cell lines.
The promoter regions of these genes contain putative transcription
factor binding sites for HNF3b/FoxA2, C/EBPs, PPARg, Pax-8, and
TTF-1. Real-time PCR showed that HNF3b/FoxA2, TTF-1, and
Pax-8 were expressed in normal thyroid tissue; in contrast, levels
were either very low or undetectable in thyroid carcinoma cell lines
(Figure 2). Western blot analysis showed that the protein
expression of PPARg was barely detectable in BHP sublines, but
easily found in ARO and FRO cell lines (data not shown).
Forced expression of either HNF3b/FoxA2 or TTF-1 in
thyroid carcinoma cells
Next, we transfected either the HNF3b/FoxA2 or the TTF-1
expression vector into papillary thyroid carcinoma cell lines.
Neither HNF3b/FoxA2- nor TTF-1-expressing BHP cells (subline
2–7) had an increase in
125I uptake, when compared with normal
FRTL-5 thyroid cells (Figure 3). Nevertheless, the forced expres-
sion of either HNF3b/FoxA2 or TTF-1 resulted in growth
inhibition compared with cells transfected with an empty vector
as measured by MTT assay (data not shown), suggesting that these
transcription factors have antiproliferative activity in papillary
thyroid carcinoma cells.
Methylation status of HNF3b/FoxA2 gene in papillary
thyroid carcinoma cells
The HNF3b/FoxA2 gene has a CpG island in its promoter; and the
region is often methylated in breast and lung cancers (Halmos et al,
2004; Miyamoto et al, 2005) prompting us to examine thyroid
carcinoma cells. The great majority of the 21 CpG sites in the
promoter were methylated in BHP (subline 2–7) and NPA papillary
thyroid carcinoma cells (Figure 4A), as well as in the anaplastic
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Figure 4 Methylation status of the CpG island of the HNF3b/FoxA2
gene. Genomic DNA of BHP (subline 2–7) and NPA cell lines (A), and
two normal thyroid glands (B) were modified by sodium bisulphate. A total
of 21 CpG sites in the CpG island of HNF3b/FoxA2 gene were analysed
by nucleotide sequencing. Methylated and unmethylated cytosines are
shown by closed and open squares, respectively. (C) BHP cells (subline
2–7) were treated either with or without 1mM 5-Az, an inhibitor of
DNA methyltransferase, for 96h. Expression of HNF3b/FoxA2 mRNA
was determined by quantitative RT–PCR. Levels of expression were
determined as a ratio between target gene and the reference gene,
b-actin. Cntl, control untreated cells. The level of HNF3b/FoxA2
expression is the mean of three samples.
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sthyroid carcinoma cell line FRO (data not shown). In contrast, the
region was unmethylated in normal thyroid tissues (Figure 4B).
Real-time PCR showed that the expression of HNF3b/FoxA2 mRNA
was induced after the treatment of BHP cells (subline 2–7) with the
demethylating agent 5-Az (1mM, 96h) (Figure 4C). Taken together,
these results suggest that the expression of the HNF3b/FoxA2 gene
is epigenetically repressed in thyroid carcinoma cell lines.
Forced expression of C/EBPb in thyroid carcinoma cells
Next, we placed a Zn-inducible C/EBPb expression vector into BHP
cells (sublines 2–7 and 7–13) (Figure 5A). CCAAT/enhancer binding
protein b has two isoforms, LAP (liver-enriched transcriptional
activating protein) and LIP (liver-enriched transcriptional inhibitory
protein). The smaller form of C/EBPb (LIP) clearly increased in the
cells treated with zinc. Induction of C/EBPb expression resulted in a
60% growth reduction compared to the non-induced cells (Figure 5B,
left panel). The more sensitive clonogenic soft agar assay showed that
clonogenic growth decreased even in the absence of zinc, suggesting
that this vector was ‘leaky’ resulting in C/EBPb expression even in
the absence of zinc. Nevertheless, clonogenic growth decreased 50%
in the presence of zinc compared with the absence of zinc (Figure 5B,
right panel). Similarly, crystal violet staining demonstrated that
C/EBPb had anti-growth activity in another subline, BHP 17-3
(Figure 5C). Taken together, these results suggested that forced
expression of C/EBPb can cause growth inhibition in BHP papillary
thyroid carcinoma cells.
Cellular localisation of C/EBPb in human normal and
papillary thyroid carcinoma tissues and cell lines
To examine expression of C/EBPb in human thyroid tissues,
normal and papillary thyroid carcinoma tissues were stained with
anti-C/EBPb antibody. Immunohistochemistry revealed that
C/EBPb signal was strongly detected in the nucleus in normal
thyroid cells (Figure 6A). Interestingly, C/EBPb was detected in the
cytoplasm and to a lesser extent the nucleus of papillary thyroid
carcinoma cells (Figure 6B). The subcellular localisation of C/EBPb
in four thyroid carcinoma cell lines (BHP2-7, NPA, FRO and ARO)
was also determined by fractionation (Figure 6C). CCAAT/
enhancer binding protein b-LAP was detected in both the nucleus
and the cytoplasm. CCAAT/enhancer binding protein b-LIP, which
has a dominant-negative activity against LAP, was expressed in
NPA and FRO cell lines, and localised in the nucleus.
DISCUSSION
We attempted to induce differentiation and inhibit proliferation of
thyroid carcinoma cells with various compounds and transcription
factors; and in addition, we explored the abnormalities in
endogenous expression of these transcription factors in thyroid
carcinoma cells. Suberoylanilide hydroxamic acid modestly
induced the expression of TPO, TG and TSHR; and the
combination of SAHA and 1,25(OH)2D3 further enhanced the
expression of NIS in BHP cell line. However, these agents were not
potent stimulators of NIS expression level, when compared with
expression levels found in normal thyroid tissues. Induced
expression of these transcripts was about 10- to 100-fold lower
than those found in normal thyroid cells. Therefore taken together,
our data suggest that these compounds had little differentiation
inducing activity and would be unlikely candidates to enhance the
therapeutic value of radioactive iodine (
131I) for the treatment of
thyroid tumours. Notably, two histone deacetylase inhibitors,
depsipeptide and Trichostatin A, have been shown to induce the
expression of NIS and
125I uptake in several follicular and
anaplastic thyroid carcinoma cell lines (Haugen, 2004).
BHP 2-7 BHP 7-13
 -actin
C/EBP  (LAP)
C/EBP  (LIP)
p
M
T
p
M
T
-
C
 
p
M
T
-
C
 
 
+
Z
n
p
M
T
p
M
T
-
C
 
p
M
T
-
C
 
 
+
Z
n
0
20
40
60
80
100
120
V
i
a
b
i
l
i
t
y
 
o
f
 
B
H
P
 
2
-
7
 
(
%
)
MTT assay
0
20
40
60
80
100
120
pMT pMT-C/EBP  pMT pMT-C/EBP 
Clonogenic assay
V
i
a
b
i
l
i
t
y
 
o
f
 
B
H
P
 
2
-
7
 
(
%
)
B
H
P
 
2
-
7
B
H
P
 
7
-
1
3
pMT-
C/EBP  pMT
pMT-
C/EBP  +Zn
Figure 5 Forced expression of C/EBPb in papillary thyroid carcinoma cells. (A) Zinc-inducible expression vector, pMT-C/EBPb (pMT-Cb), was stably
transfected into BHP cells (sublines 2–7 and 7–13). These cells were cultured either with or without 1mM zinc. Expression of two isoforms of C/EBPb, LAP
(liver-enriched transcriptional activating protein), and LIP (liver-enriched transcriptional inhibitory protein) in these cells was determined by Western blot
analysis. (B) Viability of the transfected BHP cells (subline 2–7) was measured with MTT assay (left panel) and clonogenic soft agar assay (right panel) either
in the presence or in the absence of zinc. Data represent the mean of three experiments. (C) Clonogenic growth of the Zn-inducible stably transfected BHP
cells (sublines 2–7 and 7–13) grown in soft agar and stained with crystal violet. pMT cells were cultured with Zn as control.
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had transcription factor binding sites for HNF3b/FoxA2, TTF-1,
C/EBPb, and Pax-8. Earlier studies using either the TG or
TPO promoter found that they were activated by TTF-1 and
HNF3b/FoxA2 in thyroid carcinoma cell lines (Sato and Di Lauro,
1996; Ros et al, 1999; Shimura et al, 2001). In addition, Pax-8 leads
to the re-expression of NIS, TPO, TG, and TTF-1 mRNAs in ARO
cells (Presta et al, 2005). Our present study demonstrated
that forced expression of either HNF3b/FoxA2 or TTF-1 was
unable to induce differentiation of the thyroid cancer cells as
measured by NIS mRNA expression and radioiodine uptake.
Similarly, co-transfection of HNF3b/FoxA2 and TTF-1 did
not induce the expression of TPO, TG or TSHR mRNAs in BHP
cells (data not shown), indicating that other molecule(s) might
be required to induce endogenous mRNA expression of these
thyroid-related differentiation genes. Interestingly, HNF3b/FoxA2
is a methylated gene in breast and lung cancer cells; and
overexpression of HNF3b/FoxA2 in a lung cancer cell line leads
to growth arrest and apoptosis (Halmos et al, 2004; Miyamoto
et al, 2005). Here, we report for the first time that the presence
of aberrant methylation of HNF3b/FoxA2 in thyroid carcinoma
cell lines, and forced expression of the gene, resulted in growth
inhibition.
Recently, Pome ´rance et al (2005) detected cytoplasmic localisa-
tion of C/EBPb in papillary thyroid carcinoma tissues.
Our immunohistochemical analysis also showed cytoplasmic
localisation of C/EBPb in papillary thyroid carcinoma tissues. In
addition, we demonstrated by cell fractionation that C/EBPb-LAP
was present in both the nucleus and the cytoplasm; in contrast,
C/EBPb-LIP, a dominant-negative form of C/EBPb, was localised
in the nucleus in NPA and FRO cells. Nucleocytoplasmic
distribution of C/EBPb has been found in several other types of
cancer. Human acute myeloid leukaemic cell line HL-60 showed
cytoplasmic localisation of C/EBPb-LAP when Thr235 was
phosphorylated, and the induction of differentiation and the
inhibition of proliferation of these cells by 1,25(OH)2D3 resulted in
nuclear translocation of the transcription factor (Marcinkowska
et al, 2006). In other experiments, C/EBPb phosphorylation at
Ser288 was associated with cytoplasmic localisation of the protein
in human liver cancer cells; in contrast, normal liver cells had
neither phosphorylation of Ser288 nor cytoplasmic C/EBPb
(Buck et al, 2001). CCAAT/enhancer binding protein b-LAP and
-LIP contain both nuclear localisation signal and nuclear export
signal in their common C-terminal region (Williams et al, 1997).
The N-terminal region, which is specific for C/EBPb-LAP, might
contain a motif that causes cytoplasmic retention in thyroid cancer
cells. In general, transcription factors including C/EBPb function
in the nucleus, suggesting that deregulation of nuclear localisation
of C/EBPb leads to functional deficiency and result in cell
abnormalities.
In summary, we found that the thyroid cancer cells had
decreased the expression of TTF-1 and HNF3b/FoxA2; and their
forced re-expression was associated with decreased cell growth. In
addition, methylation of HNF3b/FoxA2 and inappropriate cellular
localisation of C/EBPb were identified as novel abnormalities.
Future studies will screen for small molecules that can induce
expression of these transcription factors resulting in a unique
therapy for thyroid cancer.
GAPDH
hnRNP A1
NN N C C C CN
BHP2-7 NPA FRO ARO
C/EBP 
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LIP
Figure 6 Cellular localisation of C/EBPb by immunohistochemistry in
normal and papillary thyroid carcinoma tissues. Normal thyroid (A) and
papillary thyroid carcinoma (B) tissues were immunohistochemically
stained with anti-C/EBPb antibody. Photomicrographs are representative
of three different samples of both normal thyroid and papillary thyroid
carcinoma (data not shown). (C) Cellular fractionation of C/EBPb in
papillary and anaplastic thyroid carcinoma cells. Papillary (BHP subline 2–7
and NPA) and anaplastic thyroid carcinoma (FRO and ARO) cells were
fractionated into nuclear and cytoplasmic lysates, and the localisation of
C/EBPb was determined by electrophoresis followed by Western blot
analysis. Glyceraldehyde-3-phosphate dehydrogenase and hnRNP A1 are
cytoplasm and nucleus markers, respectively. N, nuclear fraction;
C, cytoplasmic fraction; LAP, liver-enriched transcriptional activating
protein; LIP, liver-enriched transcriptional inhibitory protein.
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